SIRT3 and metabolic dysfunction-associated steatotic liver disease: Theacrine promotes acylcarnitine metabolism in non-alcoholic fatty liver disease (NAFLD) through the SIRT3/LCAD signaling pathway, in which the target of theacrine's activities on NAFLD is identified as SIRT3 (35).